Which markets does the company export to?

Products are sold to South America, Africa, Asia, Southeast Asia, Oceania, and the Middle East.

What is the lead time for peak seasons?

The average lead time during peak seasons is one month.

Ringer Lactate Injection Medicine Infusion 500ml

Name: Ringer Lactate Injection Medicine Infusion 500ml
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2042167232

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.17-0.20

10,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

30bottles/Carton

Specification

500ml plastic bottle

Origin

China

HS Code

30049090

Production Capacity

1000000pieces/Year

Key features

Clear Liquid Formulation: Colorless clear liquid for easy visual inspection and quality assurance.

Electrolyte Balance Correction: Adjusts equilibrium of humor electrolyte acid and alkali effectively.

Metabolic Acidosis Treatment: Indicated for metabolic acid toxicosis and dehydration caused by it.

Hyperpotassaemia Support: Helps correct acid toxicosis and facilitates potassium entry into cells.

Multi-Size Availability: Available in 100ml, 250ml, 500ml, and 1000ml soft plastic bottles.

GMP Approved Manufacturing: Produced by Shijiazhuang No.4 Pharmaceutical with SFDA GMP approval.

Global Market Reach: Products exported to South America, Africa, Asia, and other regions.

Established Manufacturer: Company established in 1948 with over 3000 employees and USD58M capital.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.